Drug Profile
Research programme: kallikrein inhibitors - Vantia
Alternative Names: KKI; VA-KLK; VA118020; VA8020Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Vantia Therapeutics
- Class Small molecules
- Mechanism of Action Kallikrein inhibitors; Tissue kallikrein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Asthma; Diabetes mellitus; Hereditary angioedema; Inflammation; Respiratory tract disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Asthma in United Kingdom (PO)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Diabetes-mellitus in United Kingdom
- 16 Jul 2016 No recent reports of development identified for preclinical development in Hereditary-angioedema in United Kingdom (PO)